Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Tandem Diabetes Care's Enterprise Value is $1,214 Mil.
Tandem Diabetes Care's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was $-92 Mil. Therefore, Tandem Diabetes Care's EV-to-EBIT ratio for today is -13.25.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Tandem Diabetes Care's Enterprise Value is $1,214 Mil.
Tandem Diabetes Care's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-74 Mil. Therefore, Tandem Diabetes Care's EV-to-EBITDA ratio for today is -16.46.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Tandem Diabetes Care (LTS:0M0F) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Tandem Diabetes Care's current Enterprise Value is $1,214 Mil.
Tandem Diabetes Care's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-92 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Tandem Diabetes Care's current Enterprise Value is $1,214 Mil.
Tandem Diabetes Care's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-74 Mil.
Tandem Diabetes Care's current Enterprise Value is $1,214 Mil.
Tandem Diabetes Care's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $1,028 Mil.
Tandem Diabetes Care's current Enterprise Value is $1,214 Mil.
Tandem Diabetes Care's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $20 Mil.
Tandem Diabetes Care's current Enterprise Value is $1,214 Mil.
Tandem Diabetes Care's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-39 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care Enterprise Value Related Terms
Tandem Diabetes Care Enterprise Value Historical Data
* Premium members only.
The historical data trend for Tandem Diabetes Care's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0M0F vs CNMD, AORT, LMRI: Enterprise Value Comparison
For the Medical Devices subindustry, Tandem Diabetes Care's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tandem Diabetes Care Enterprise Value vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Tandem Diabetes Care's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Tandem Diabetes Care's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Tandem Diabetes Care's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tandem Diabetes Care (LTS:0M0F) has a Enterprise Value of $1,214 Mil as of Jul. 03, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Tandem Diabetes Care and its competitors.
Is Tandem Diabetes Care's Enterprise Value too high?
Tandem Diabetes Care's current Enterprise Value is $1,214 Mil. Overall, Tandem Diabetes Care has a GF Score™ of 68/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Tandem Diabetes Care's Enterprise Value compare to CNMD and AORT?
Tandem Diabetes Care's Enterprise Value of $1,214 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Medical Devices & Instruments company?
A good Enterprise Value depends on the Medical Devices & Instruments industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Tandem Diabetes Care and its competitors. Tandem Diabetes Care's current Enterprise Value is $1,214 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tandem Diabetes Care stock overvalued right now?
Based on GuruFocus' analysis, Tandem Diabetes Care (LTS:0M0F) is currently considered Possible Value Trap. The stock's GF Value™ is $29.76, compared to a current price of $15.63 — trading 47.5% below its estimated fair value. The current Enterprise Value is $1,214 Mil. Tandem Diabetes Care's overall GF Score™ is 68/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Tandem Diabetes Care (LTS:0M0F), the current Enterprise Value is $1,214 Mil as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tandem Diabetes Care (LTS:0M0F) Overvalued in 2026?
Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued.
The current stock price of $15.63 is trading 47.5% below its estimated GF Value™ of $29.76.
GuruFocus considers Tandem Diabetes Care to be Possible Value Trap.
Key valuation signals for LTS:0M0F:
Enterprise Value: $1,214 Mil
GF Value™: $29.76 vs. price of $15.63 (47.5% below fair value)
No single metric tells the full story. See the LTS:0M0F stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
68GF Score
Get the complete analysis for LTS:0M0F
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0M0F has been successfully added to your 
